• Instil Bio posted a GAAP net loss per share of $0.63 for Q2 2026, narrowing from $3.24 a year earlier.
• Non-GAAP net loss per share was $0.45, improving from $2.88 in the prior-year quarter.
• R&D expense fell to $0.3 million from $6.7 million, while G&A declined to $5.1 million from $6.2 million.
• Cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million at June 30, down from $76.3 million at Dec. 31.
• Instil is evaluating potential acquisitions and in-licensing opportunities, forecasting its cash runway extends beyond 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instil Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001789769-26-000055), on August 13, 2026, and is solely responsible for the information contained therein.